Oragenics, Inc. Announces Conversion of Preferred Shares and Elimination of Liquidation Preference

Group 1 - Oragenics, Inc. has converted its remaining outstanding convertible Series A and Series B Preferred Shares into common stock, simplifying its capital structure and eliminating approximately $2.35 million in liquidation preference [1][2][3] - The conversion involved 5,417,000 Series A Preferred Shares and 4,050,000 Series B Preferred Shares, resulting in the issuance of approximately 22,000 common shares [2] - The Chief Financial Officer of Oragenics stated that this conversion is a pivotal step in strengthening the company's foundation for future growth and aligns with its commitment to creating long-term value for shareholders [3] Group 2 - Oragenics is focused on developing innovative treatments for brain-related health conditions, including drug candidates for mild traumatic brain injury and Niemann Pick Disease Type C [4]